FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to medicine and pharmaceutics, specifically to use of a composition containing silybin, for producing a medicament for treating metabolic oxidative changes in non-alcoholic steatohepatitis (NASH), wherein the treatment of the patients having the modified lipid profile is performed, wherein the patients having the altered lipid profile show a high TBARS value in the TBARS test in relation to healthy subjects, wherein said healthy subjects demonstrate a TBARS value of 0.01 ± 0.002 mcM/mcg of the protein.
EFFECT: invention enables the effective treatment of NASH in a specific group of patients having an elevated level of TBARS relative to value of 0,01 ± 0,002 mcM/mcg of protein.
6 cl, 2 dwg, 5 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION CONTAINING SILYBIN | 2016 |
|
RU2697523C2 |
| METHOD OF TREATING NON-ALCOHOLIC STEATOHEPATITIS (NASH) WITH USING CYSTEAMINE PRODUCTS | 2008 |
|
RU2498795C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING SILYBIN AND RADIX PUERARIAE EXTRACT | 2016 |
|
RU2697670C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING SILYBIN AND VITAMIN E | 2016 |
|
RU2695806C2 |
| TREATMENT OF HEPATIC ADIPOSITIS WITH APPLICATION OF GLUCOCORTICOID AND MINERALOCORTICOID RECEPTOR ANTAGONISTS | 2015 |
|
RU2718921C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING SILYBIN AND L-CARNITINE | 2016 |
|
RU2699011C2 |
| METHOD FOR CORRECTION OF METABOLIC DISORDERS AND SYSTEM OF ANTIOXIDANT PROTECTION IN METABOLIC SYNDROME WITH FATTY LIVER INVOLVEMENT | 2019 |
|
RU2701159C1 |
| METHOD OF IMPROVEMENT OF LIVER FUNCTION | 2013 |
|
RU2653478C2 |
| PHARMACEUTICAL COMBINATION CONTAINING SILYBIN | 2016 |
|
RU2695224C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING SILYBIN, VITAMIN E AND L-CARNITINE | 2016 |
|
RU2700793C2 |
